Analysis of expression of PTEN/PI3K pathway and programmed cell death ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM)
- 1 June 2016
- journal article
- Published by Elsevier in Lung Cancer
- Vol. 96, 1-6
Abstract
No abstract availableKeywords
Funding Information
- Paolo Nuciforo and Jose Jimenez for excellent technical assistance with FFPE and immunohistochemistry
- Marta Vilaro for statistical support and Francisco Sánchez Vélez for graphic design
This publication has 42 references indexed in Scilit:
- PTEN Loss Increases PD-L1 Protein Expression and Affects the Correlation between PD-L1 Expression and Clinical Parameters in Colorectal CancerPLOS ONE, 2013
- Exploratory analysis of activation of PTEN–PI3K pathway and downstream proteins in malignant pleural mesothelioma (MPM)Lung Cancer, 2012
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerNew England Journal of Medicine, 2012
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- Tumor-Expressed B7-H1 and B7-DC in Relation to PD-1+ T-Cell Infiltration and Survival of Patients with Cervical CarcinomaClinical Cancer Research, 2009
- PD‐1 signaling in primary T cellsImmunological Reviews, 2009
- PD-1 and Its Ligands in Tolerance and ImmunityAnnual Review of Immunology, 2008
- Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+T lymphocytes are prognostic factors of human ovarian cancerProceedings of the National Academy of Sciences, 2007
- Perturbations of the AKT signaling pathway in human cancerOncogene, 2005
- Selective Activation of Insulin Receptor Substrate-1 and -2 in Pleural Mesothelioma CellsCancer Research, 2004